Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...
Although a plethora of medications and therapies now exist for major depression, roughly one in three diagnosed patients ...
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company ...
It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met ...
A new study published in the Journal of Affective Disorders has found that adults with major depression show specific ...
While not an official condition, this wave of depressive-like symptoms can be overwhelming. Therapists share the red flags ...
A generative AI–powered therapy chatbot is linked to significant reductions in symptoms of depression, anxiety, and eating ...
A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...
Investor's Business Daily on MSN2d
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A WeekAxsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.
Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...
Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...
Discover the 6 types of depression affecting millions of Americans, their causes, warning signs, and effective treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback